Effects of receptor tyrosine kinase inhibitor A47 on estrogen and growth factor-dependent breast cancer cell proliferation and apoptosis in vitro

Journal of Surgical Oncology

Volumn 79, Issue 1, 2002, Pages 17-29

  Murthy, Satya ^a   Liu, Naxin M ^a   Yang, Xiaohe ^a   Twaddle, George M ^a   Turbov, Jane M ^a  

^a EVANSTON NORTHWESTERN HEALTHCARE   (United States)

Author keywords

Growth substances; Signal transduction; Tyrphostins

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; EPIDERMAL GROWTH FACTOR; ESTROGEN; GROWTH FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SOMATOMEDIN; TYRPHOSTIN; TYRPHOSTIN A47; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CELL CYCLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; ESTROGEN THERAPY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; MITOSIS INHIBITION; MULTIVARIATE ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL CYCLE; EPIDERMAL GROWTH FACTOR; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; FIBROBLAST GROWTH FACTORS; FLOW CYTOMETRY; HUMANS; IN SITU NICK-END LABELING; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, HORMONE-DEPENDENT; POSTMENOPAUSE; PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; SURVIVORS; TUMOR CELLS, CULTURED; TYRPHOSTINS;

EID: 0036140989     PISSN: 00224790     EISSN: None     Source Type: Journal    
DOI: 10.1002/jso.10033     Document Type: Article

References (58)

1. Estrogen replacement therapy in breast cancer survivors. A time for change
2. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the Nurses' Health Study
3. Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of postmenopausal women
4. The effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease
5. Estrogen stakes claim to cognition (Research News)
6. Postmenopausal hormone therapy and mortality
7. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women
8. Menopausal estrogen replacement therapy in women with breast cancer
9. Hormone replacement therapy in women treated for breast cancer
10. Replacement therapy for breast cancer survivors. A pilot study
11. Estrogen-replacement therapy after breast cancer
12. Secreted and cellular polypeptide patterns of MCF-7 human breast cancer cells following either estrogen stimulation or v-H-ras transfection
13. Constitutive Raf-1 kinase activity in breast cancer cells induces both estrogen-independent growth and apoptosis
14. Regulation of cyclin B1 by estradiol and polyamines in MCF-7 breast cancer cells
15. c-Myc or cyclin D1 mimics estrogen effects on cyclin E-Cdk2 activation and cell cycle reentry
16. Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily: Role as anticancer agents
17. The role of the epidermal growth factor receptor and the c-erbB-2 protein in breast cancer
18. The paradoxical regulation of protein phosphorylation in insulin action
19. Introduction to steroids in the menopause
20. Functional estrogen receptors in a human preosteoclastic cell line
21. Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis
22. Tyrosine kinase inhibition: An approach to drug development
23. Selective platelet-derived growth factor receptor kinase blockers reverse sistransformation
24. Specific inhibition of insulin-like growth factor-1 and insulin receptor tyrosine kinase activity and biological function of tyrphostins
25. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase
26. Tyrphostins 6. Dimeric benzylidenemalononitrile tyrophostins: Potent inhibitors of EGF receptor tyrosine kinase in vitro
27. Quercetin: Inhibition of signal transduction activity in human breast carcinoma MDA-MB-435 cell line
28. Phase II trial of suramin in patients with advanced renal cell carcinoma: Treatment results, pharmacokinetics, and tumor growth factor expression
29. Selective inhibition of the epidermal growth factor and HER/2neu receptors by tyrphostins
30. Inhibition of breast cancer cell growth in vitro by a tyrosine kinase inhibitor
31. Mechanism of action of a tyrphostin, 3,4-dihydroxy-alpha-cyanothiocinnamamide, in breast cancer cell growth inhibition involves the suppression of cyclin B1 and the functional activity of cyclin B1/p34cdc2 complex
32. Tyrosine kinase inhibitors as antiproliferative agents against an estrogen-dependent breast cancer cell line in vitro
33. The antiproliferative effects of tyrosine kinase inhibitors tyrphostins on a human squamous cell carcinoma in vitro and in nude mice
34. Isolation and characterization of A-431 cells that retain high epidermal growth factor binding capacity and respond to epidermal growth factor by growth stimulation
35. Uptake of a boronated epidermal growth factor-dextran conjugate in CHO xenografts with and without human EGF-receptor expression
36. Granzyme B mimics apical caspases. Description of a unified pathway for transactivation of executioner caspase-3 and -7
37. Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis
38. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays
39. Detection of DNA strand breaks in individual apoptotic cells by the in situ terminal deoxynucleotidyl transferase and nick translation assays
40. Sequential activation of ICE-like and CPP32-1ike proteases during Fas-mediated apoptosis
41. PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner
42. Blockade of the epidermal growth factor receptor inhibits transforming growth factor alpha-induced but not estrogen-induced growth of hormone-dependent human breast cancer
43. Effects of estrogen on apoptotic pathways in human breast cancer cell line MCF-7
44. The role of estrogen in he regulation of EGFR expression
45. All trans retinoic acid (ATRA)-induced apoptosis is preceded by G1 arrest in human MCF-7 breast cancer cells
46. Inhibition of Cdk2 activation by selected tyrphostins causes cell cycle arrest at late G1 and S phase
47. Epidermal growth factor receptor signaling cascade as target for tyrphostin (RG 50864) in epithelial cells. Paradoxical effects on mitogen-activated protein kinase kinase and mitogen-activated protein kinase activities
48. Inhibition of platelet activation by tyrosine kinase inhibitors
49. Estradiol-induced phosphorylation of serine 118 in the estrogen receptor is independent of p42/p44 mitogen-activated protein kinase
50. Differential crosstalk of estrogen and growth factor receptors in two human mammary tumor cell lines
51. Cytoskeletal association of epidermal growth factor receptor and associated signaling proteins is regulated by cell density in IEC-6 intestinal cells
52. TGF beta in prostate cancer: A growth inhibitor that can enhance tumorigenicity
53. Inhibition of the epidermal growth factor receptor family of tyrosine kinases as an approach to cancer chemotherapy: Progression from reversible to irreversible inhibitors
54. Epidermal growth factor receptor-targeted approaches for anticancer therapy: Focus on ZD1839
55. Status of bcr-abl tyrosine kinase inhibitors in chronic myelogenous leukemia
56. The epidermal growth factor receptor family as a target for cancer therapy